244 related articles for article (PubMed ID: 21526954)
1. Molecular diagnostics of gliomas.
Nikiforova MN; Hamilton RL
Arch Pathol Lab Med; 2011 May; 135(5):558-68. PubMed ID: 21526954
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic markers in gliomas.
Ducray F; El Hallani S; Idbaih A
Curr Opin Oncol; 2009 Nov; 21(6):537-42. PubMed ID: 19667985
[TBL] [Abstract][Full Text] [Related]
3. [Classification of gliomas. Current progress and perspectives].
Capper D; Reifenberger G
Nervenarzt; 2015 Jun; 86(6):672, 674-6, 678-80, passim. PubMed ID: 25989737
[TBL] [Abstract][Full Text] [Related]
4. Updates in prognostic markers for gliomas.
Aquilanti E; Miller J; Santagata S; Cahill DP; Brastianos PK
Neuro Oncol; 2018 Nov; 20(suppl_7):vii17-vii26. PubMed ID: 30412261
[TBL] [Abstract][Full Text] [Related]
5. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
Chen SC; Lo CM; Wang SH; Su EC
BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
[TBL] [Abstract][Full Text] [Related]
6. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
7. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
8. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
[TBL] [Abstract][Full Text] [Related]
9. A surgical strategy for lower grade gliomas using intraoperative molecular diagnosis.
Koriyama S; Nitta M; Kobayashi T; Muragaki Y; Suzuki A; Maruyama T; Komori T; Masui K; Saito T; Yasuda T; Hosono J; Okamoto S; Shioyama T; Yamatani H; Kawamata T
Brain Tumor Pathol; 2018 Jul; 35(3):159-167. PubMed ID: 29980868
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice].
Fontaine D; Vandenbos F; Lebrun C; Paquis V; Frenay M
Rev Neurol (Paris); 2008; 164(6-7):595-604. PubMed ID: 18565359
[TBL] [Abstract][Full Text] [Related]
11. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ
Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866
[TBL] [Abstract][Full Text] [Related]
12. [How molecular biology can improve the clinical diagnosis of gliomas?].
D'Haene N; Blanchard O; De Nève N; Evens J; Maris C; Rorive S; Le Mercier M; Salmon I
Rev Med Brux; 2016; 37(3):152-158. PubMed ID: 28525188
[TBL] [Abstract][Full Text] [Related]
13. Molecular diagnostics of gliomas: state of the art.
Riemenschneider MJ; Jeuken JW; Wesseling P; Reifenberger G
Acta Neuropathol; 2010 Nov; 120(5):567-84. PubMed ID: 20714900
[TBL] [Abstract][Full Text] [Related]
14. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Malzkorn B; Reifenberger G
Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
[TBL] [Abstract][Full Text] [Related]
15. Molecular Classification of Diffuse Gliomas.
Kalidindi N; Or R; Babak S; Mason W
Can J Neurol Sci; 2020 Jul; 47(4):464-473. PubMed ID: 31918786
[TBL] [Abstract][Full Text] [Related]
16. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
17. Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics.
Perry A; Fuller CE; Banerjee R; Brat DJ; Scheithauer BW
Front Biosci; 2003 Jan; 8():a1-9. PubMed ID: 12456321
[TBL] [Abstract][Full Text] [Related]
18. Molecular diagnostics of gliomas: the clinical perspective.
Tabatabai G; Stupp R; van den Bent MJ; Hegi ME; Tonn JC; Wick W; Weller M
Acta Neuropathol; 2010 Nov; 120(5):585-92. PubMed ID: 20862485
[TBL] [Abstract][Full Text] [Related]
19. Molecular genetic markers as predictors of response to chemotherapy in gliomas.
Idbaih A; Omuro A; Ducray F; Hoang-Xuan K
Curr Opin Oncol; 2007 Nov; 19(6):606-11. PubMed ID: 17906460
[TBL] [Abstract][Full Text] [Related]
20. MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
Zhou H; Vallières M; Bai HX; Su C; Tang H; Oldridge D; Zhang Z; Xiao B; Liao W; Tao Y; Zhou J; Zhang P; Yang L
Neuro Oncol; 2017 Jun; 19(6):862-870. PubMed ID: 28339588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]